Partnering
Partnering
We are actively seeking strategic partnerships and collaborations to fully leverage the therapeutic potential of our pipeline and technology platform
Our differentiated single-cell profiling capabilities can accelerate and de-risk the clinical development of novel therapeutics. Our CelliGOTM platform and unique DISTM capabilities accelerate the discovery and development of high-quality therapeutic antibodies. They enable biomarker discovery for advanced patient stratification and enhanced probability of clinical success.
We are currently working with pharma partners to discover and validate novel therapeutic targets and to identify rare functional antibodies against complex targets.
Our key partnership interests include
Pipeline
- Partnering our advanced immunomodulatory programs
- Identifying novel targets and immunomodulation mechanisms
- Out-licensing opportunities
Platform
- Advanced development of single-cell platform tailored to development needs
- Identifying novel targets
- Generating high quality therapeutic antibodies against complex targets (GPCR, ion channels)
- Discovering and validating biomarkers
- Discovering therapeutics and antibodies from patient samples
- Profiling tumor microenvironment
Pipeline
- Partnering our advanced immunomodulatory programs
- Identifying novel targets and immunomodulation mechanisms
- Out-licensing opportunities
Platform
- Advanced development of single-cell platform tailored to development needs
- Identifying novel targets
- Generating high quality therapeutic antibodies against complex targets (GPCR, ion channels)
- Discovering and validating biomarkers
- Discovering therapeutics and antibodies from patient samples
- Profiling tumor microenvironment
Partnership Highlights
HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis for HFB200603
Read more
HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis for HFB200301
Read More
FibroGen, Inc. and HiFiBiO Therapeutics, announced an extension of their partnership
Read More
HiFiBiO Therapeutics announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC)
Read More
FibroGen, Inc. and HiFiBiO Therapeutics, announced a partnership covering three HiFiBiO programs.
Read More
Kite and HiFiBio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
Read More
Research Collaboration to Develop Technology for the Treatment of Cancer
Read More
Research Collaboration to Develop Technology for the Treatment of Cancer
Read More
